单克隆抗体在肝素诱导的血小板缺血的发病过程中
Jared Treverton1,2, Donald M Arnold2,3, Daniil G Ivanov4
1Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.
The New England journal of medicine
|September 3, 2025
概括
肝素诱导的血小板缺血 (HIT) 的致病抗体是单克隆的,而不是多克隆的. 在HIT患者中的这一发现为疾病机制和潜在的诊断和治疗进步提供了新的见解.
科学领域:
- 免疫学
- 血液学
- 分子生物学
背景情况:
- 肝素诱导的血小板缺血 (HIT) 是一种免疫媒介的血小板疾病.
- HIT是由针对血小板因子4 (PF4) - 肝素复合体的抗体触发的.
- 以前,HIT被认为是一种多克隆性免疫反应,但相关疾病显示出克隆性限制.
研究的目的:
- 调查肝素诱导的血小板缺血 (HIT) 中的病原性抗体的克隆性.
- 要确定HIT抗体是单克隆的还是多克隆的.
- 了解HIT诊断和治疗的影响.
主要方法:
- 通过使用PF4肝素颗粒的9名HIT患者血清的亲属性净化抗体.
- 通过免疫固定电泳和质谱测量评估抗体克隆性.
- 使用酶免疫试验和P-选择蛋白表达试验评估抗体结合和血小板激活.
主要成果:
- 所有9个HIT患者的样本都显示了针对PF4- 肝素的血小板激活抗体.
- 在67%的样本中检测到单克隆抗体;质谱检测证实了所有纯化的抗体的单克隆性.
- 纯化的抗体激活了血小板,而耗尽的血清失去了活性,证实了致病性抗体的去除.
结论:
- 所有研究的HIT患者的致病抗体都是单克隆的.
- 这一发现澄清了HIT的病原性.
- 结果表明改善了HIT的诊断和治疗策略.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Hybridoma Technology
15.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.3K
Antibody Actions
1.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22


